However, findings from the AURA3 trial demonstrated that NSCLC patients harboring T790M mutations and treated with osimertinib achieved a great response, with an ORR of 71% after progressing on first-line EGFR-TKI therapy [12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.